NO790059L - Fremgangsmaate for fremstilling av prostaglandinholdige terapeutiske preparater - Google Patents
Fremgangsmaate for fremstilling av prostaglandinholdige terapeutiske preparaterInfo
- Publication number
- NO790059L NO790059L NO790059A NO790059A NO790059L NO 790059 L NO790059 L NO 790059L NO 790059 A NO790059 A NO 790059A NO 790059 A NO790059 A NO 790059A NO 790059 L NO790059 L NO 790059L
- Authority
- NO
- Norway
- Prior art keywords
- oil
- trans
- prostaglandin
- prostaglandins
- esters
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 15
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 235000014571 nuts Nutrition 0.000 claims description 3
- 150000002482 oligosaccharides Polymers 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229940116333 ethyl lactate Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- -1 prostaglandin salt Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical class CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-VBJOUPRGSA-N triricinolein Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC)COC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-VBJOUPRGSA-N 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH46378 | 1978-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO790059L true NO790059L (no) | 1979-07-18 |
Family
ID=4187587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO790059A NO790059L (no) | 1978-01-17 | 1979-01-09 | Fremgangsmaate for fremstilling av prostaglandinholdige terapeutiske preparater |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS54110313A (xx) |
| AR (1) | AR218518A1 (xx) |
| AU (1) | AU4337979A (xx) |
| BE (1) | BE873481A (xx) |
| DD (1) | DD141260A5 (xx) |
| DE (1) | DE2900428A1 (xx) |
| DK (1) | DK7679A (xx) |
| ES (1) | ES476857A1 (xx) |
| FI (1) | FI790043A (xx) |
| FR (1) | FR2414336A1 (xx) |
| GB (1) | GB2012168A (xx) |
| GR (1) | GR72910B (xx) |
| IL (1) | IL56435A0 (xx) |
| IT (1) | IT7947665A0 (xx) |
| NL (1) | NL7900255A (xx) |
| NO (1) | NO790059L (xx) |
| NZ (1) | NZ189380A (xx) |
| PT (1) | PT69073A (xx) |
| SE (1) | SE7900124L (xx) |
| ZA (1) | ZA79199B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024676A (en) * | 1958-11-28 | 1962-03-13 | Sack Gmbh Maschf | Hydraulic presses |
| US4211793A (en) * | 1979-03-19 | 1980-07-08 | American Cyanamid Company | Triethyl citrate solutions of PGE-type compounds |
| US4310543A (en) * | 1980-10-09 | 1982-01-12 | Hoffmann-La Roche Inc. | Prostaglandin compositions |
| CH651756A5 (de) * | 1982-02-05 | 1985-10-15 | Sandoz Ag | Pharmazeutikum in form einer suspension enthaltend thioridazin. |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| JPS60116628A (ja) * | 1983-11-29 | 1985-06-24 | Teijin Ltd | ７−チアプロスタグランジンｅ↓１類製剤用組成物 |
| JPS60169430A (ja) * | 1984-02-14 | 1985-09-02 | Teijin Ltd | プロスタグランジン類製剤用組成物 |
| JPS6191136A (ja) * | 1984-10-09 | 1986-05-09 | Teijin Ltd | プロスタグランジン類製剤用組成物 |
| JPS61289034A (ja) * | 1985-06-17 | 1986-12-19 | Teijin Ltd | イソカルバサイクリン類脂肪乳剤 |
| JPH04342530A (ja) * | 1991-04-26 | 1992-11-30 | Teijin Ltd | ７−フルオロプロスタサイクリン類脂肪乳剤 |
| WO2009026434A1 (en) * | 2007-08-21 | 2009-02-26 | Alkermes, Inc. | Pulmonary pharmaceutical formulations |
-
1979
- 1979-01-08 DK DK7679A patent/DK7679A/da not_active Application Discontinuation
- 1979-01-08 SE SE7900124A patent/SE7900124L/xx unknown
- 1979-01-08 DE DE19792900428 patent/DE2900428A1/de not_active Withdrawn
- 1979-01-08 FI FI790043A patent/FI790043A/fi unknown
- 1979-01-09 NO NO790059A patent/NO790059L/no unknown
- 1979-01-12 NL NL7900255A patent/NL7900255A/xx not_active Application Discontinuation
- 1979-01-12 GB GB791192A patent/GB2012168A/en not_active Withdrawn
- 1979-01-15 BE BE0/192900A patent/BE873481A/xx unknown
- 1979-01-15 PT PT69073A patent/PT69073A/pt unknown
- 1979-01-15 DD DD79210477A patent/DD141260A5/de unknown
- 1979-01-15 ES ES476857A patent/ES476857A1/es not_active Expired
- 1979-01-15 IL IL56435A patent/IL56435A0/xx unknown
- 1979-01-15 NZ NZ189380A patent/NZ189380A/xx unknown
- 1979-01-15 AU AU43379/79A patent/AU4337979A/en not_active Abandoned
- 1979-01-16 AR AR275179A patent/AR218518A1/es active
- 1979-01-16 GR GR58106A patent/GR72910B/el unknown
- 1979-01-17 ZA ZA79199A patent/ZA79199B/xx unknown
- 1979-01-17 IT IT7947665A patent/IT7947665A0/it unknown
- 1979-01-17 JP JP443079A patent/JPS54110313A/ja active Pending
- 1979-01-17 FR FR7901110A patent/FR2414336A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT7947665A0 (it) | 1979-01-17 |
| FR2414336A1 (fr) | 1979-08-10 |
| AU4337979A (en) | 1979-07-26 |
| DE2900428A1 (de) | 1979-07-19 |
| AR218518A1 (es) | 1980-06-13 |
| PT69073A (fr) | 1979-02-01 |
| DD141260A5 (de) | 1980-04-23 |
| NL7900255A (nl) | 1979-07-19 |
| GB2012168A (en) | 1979-07-25 |
| NZ189380A (en) | 1981-01-23 |
| FR2414336B1 (xx) | 1981-07-31 |
| SE7900124L (sv) | 1979-07-18 |
| ES476857A1 (es) | 1979-05-16 |
| GR72910B (xx) | 1984-01-04 |
| ZA79199B (en) | 1980-08-27 |
| IL56435A0 (en) | 1979-03-12 |
| BE873481A (fr) | 1979-07-16 |
| FI790043A (fi) | 1979-07-18 |
| DK7679A (da) | 1979-07-18 |
| JPS54110313A (en) | 1979-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1263604A (en) | Pharmaceutical oil-in-water type micro-emulsion | |
| NO790059L (no) | Fremgangsmaate for fremstilling av prostaglandinholdige terapeutiske preparater | |
| EP1232139B1 (en) | Nervonic acid derivatives, their preparation and use | |
| SU1321372A3 (ru) | Способ получени оптически активных или рацемических производных 13,14-дидегидропростагландинов | |
| US3337402A (en) | Stable and palatable pharmaceutical composition | |
| US7674921B2 (en) | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | |
| JPS61501775A (ja) | 心臓障害の処置または予防用の医薬組成物および方法 | |
| KR930001835B1 (ko) | 신규 히단토인(Hydantoin) 유도체의 제조방법 | |
| JPH03204853A (ja) | プロスタグランジン類縁体およびその脂肪乳剤 | |
| EP0600395A1 (en) | Antinflammatory and analgesic diclofenac gel preparation | |
| US6600060B2 (en) | CLA-esters | |
| CN101284003B (zh) | 含穿心莲内酯衍生物的药物组合物及其制备方法与用途 | |
| TW200911273A (en) | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound | |
| US4081529A (en) | Polyhydroxyphenylchromanones | |
| AU2001233286A1 (en) | Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension | |
| CN102803243A (zh) | 二硫辛酸哌嗪酯及含有二硫辛酸哌嗪酯的药物组合物 | |
| EP0074411B1 (en) | Ascorbic acid derivatives | |
| CN107205982A (zh) | 一种黄酮化合物的药物组合物及其用途 | |
| EP2036575B1 (en) | Pharmaceutical compositions for oral use for treating patients affected by obesity | |
| CN102727608A (zh) | 一种纳多洛尔、苹果籽油纳米乳抗高血压药物 | |
| Zhang et al. | In vivo stimulation of insulin secretion by novel esters of succinic acid | |
| US3928602A (en) | Substituted phenoxymalonic acids, esters thereof and hypolipaemic agents containing the same for lowering lipid levels | |
| US3819705A (en) | Quaternary salts of tri-(beta-propyloxyethyl)amine derivatives and process for producing same | |
| EP0183237B1 (en) | Process for making a stable pharmaceutical preparation of prostaglandin e compounds, and/or 15r forms thereof | |
| NO174887B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive aryl- alkyl-pyrrol-2-carboxylsyreforbindelser |